Healius (ASX:HLS) YoY EPS Growth: -133.33% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:HLS Healius Ltd ASX:HLS
42 GF Score
Price A$0.42
GF Value A$1.02
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Healius YoY EPS Growth?

Healius ASX:HLS +1.20% 42 YoY EPS Growth is -133.33% as of Dec. 2025. GuruFocus rates ASX:HLS with a GF Score™ of 42/100 and a GF Value™ of A$1.02 (Possible Value Trap). The stock has 7 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Healius's YoY EPS Growth for the quarter that ended in Dec. 2025 was -133.33%.

Healius's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was A$-0.04.

Healius YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Healius's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Healius YoY EPS Growth Chart

Healius Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 161.90 640.00 -224.12 -63.99 78.75

Healius Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,226.09 116.52 98.32 -308.79 -133.33
ASX:HLS
42GF Score
Healius Ltd ASX:HLS
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Healius YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Healius's YoY EPS Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EPS Growth (A: Jun. 2025 )
=(Earnings per Share (Diluted) (A: Jun. 2025 )-Earnings per Share (Diluted) (A: Jun. 2024 ))/ | Earnings per Share (Diluted) (A: Jun. 2024 ) |
=(-0.208--0.979)/ | -0.979 |
=78.75 %

Healius's YoY EPS Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EPS Growth (Q: Dec. 2025 )
=(Earnings per Share (Diluted) (Q: Dec. 2025 )-Earnings per Share (Diluted) (Q: Dec. 2024 )) / | Earnings per Share (Diluted) (Q: Dec. 2024 )) |
=(-0.042--0.018)/ | -0.018 |
=-133.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of -133.33% mean?
Healius (ASX:HLS) has a YoY EPS Growth of -133.33% as of Dec. 2025. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Healius and its competitors.
Is Healius' YoY EPS Growth too high?
Healius' current YoY EPS Growth is -133.33%. Overall, Healius has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Healius' YoY EPS Growth compare to TMO and DHR?
Healius' YoY EPS Growth of -133.33% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Medical Diagnostics & Research company?
A good YoY EPS Growth depends on the Medical Diagnostics & Research industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Healius and its competitors. Healius's current YoY EPS Growth is -133.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healius stock overvalued right now?
Based on GuruFocus' analysis, Healius (ASX:HLS) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.02, compared to a current price of A$0.42 — trading 58.8% below its estimated fair value. The current YoY EPS Growth is -133.33%. Healius' overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Healius (ASX:HLS), the current YoY EPS Growth is -133.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healius (ASX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, Healius stock appears to be undervalued. The current stock price of A$0.42 is trading 58.8% below its estimated GF Value™ of A$1.02. GuruFocus considers Healius to be Possible Value Trap.

Key valuation signals for ASX:HLS:

  • YoY EPS Growth: -133.33%
  • GF Value™: A$1.02 vs. price of A$0.42 (58.8% below fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Healius Business Description

Other Exchanges PGZ:Germany
Address 161 Castlereagh Street, Level 22, Sydney, NSW, AUS, 2000
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
42GF Score

Get the complete analysis for ASX:HLS

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42
Price
A$1.02
GF Value